Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C

PLoS One. 2021 Dec 20;16(12):e0260608. doi: 10.1371/journal.pone.0260608. eCollection 2021.

Abstract

Introduction: Prevalence of chronic hepatitis C (CHC) is higher in patients born between 1955-1975. The aim was to perform an economic evaluation of an age-based electronic health record (EHR) alert in primary care to detect patients with undiagnosed CHC and its treatment in comparison with non-use of the alert system, in Valencian Community, Spain.

Materials and methods: Decision trees and Markov model were used to evaluate the diagnosis and progression of the disease, respectively. CHC was diagnosed by serology and viral load in seropositive subjects. Epidemiological data and diagnostic costs were extracted from public sources of the Valencian Community. Probabilities, utilities and costs of model states were obtained from the literature. The impact on mortality and hepatic complications avoided by the implementation of the alert were estimated, and efficiency was measured as an incremental cost-utility ratio (ICUR) based on quality-adjusted life years (QALYs) and the costs of both alternatives.

Results: The EHR alert detected 269,548 patients, of whom 1,331 had CHC (vs. 23 patients with non-alert). Over the patients' lifetime, the alert would prevent 93% of decompensated cirrhosis cases, 87% of hepatocellular carcinomas, 90% of liver transplants, and 89% of liver related deaths compared to non-use of the alert system. In addition, it would obtain an additional 3.3 QALY per patient, with an incremental cost of €10,880 and an ICUR of €3,321.

Conclusions: The implementation of an age-based EHR alert in primary care to detect patients with CHC reduces hepatic complications and mortality and is an efficient strategy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Electronic Health Records
  • Health Care Costs
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / diagnosis*
  • Hepatitis C, Chronic / pathology
  • Humans
  • Liver Diseases / etiology
  • Liver Diseases / mortality
  • Markov Chains
  • Middle Aged
  • Primary Health Care / economics*
  • Primary Health Care / methods
  • Quality-Adjusted Life Years
  • Severity of Illness Index
  • Spain
  • Survival Analysis

Grants and funding

AGH has received funding for the development of the project not conditional upon the results from Gilead Sciences Spain. RDH and MAC received funding in the form of salary from Pharmacoeconomics & Outcomes Research Iberia (PORIB) that has received financing from Gilead Sciences Spain for the development of the project that is not conditional upon the results. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.